Lotus Eye Hospital & Institute
Healthcare Services
LOTUSEYE NSE
₹106.52 −2.17 (−2.00%)
- P/E
- 1521.71
Close 4 Nov 2026 ₹106.52 −16.71 −13.6% 1Y
Start ₹123.23
Key Fundamentals
MicrocapHealthcare ServicesHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 1.41%
- Debt to Equity
- 0.26
- EPS (TTM)
- ₹0.07
- Book Value
- ₹28.92
- Market Cap
- —
- P/E (TTM)
- 1521.71
- P/B
- 3.68
- ROE
- 0.13%
- Dividend Yield
- 0.46%
- EBITDA
- ₹4.60 Cr
- 52W High
- ₹147.00
- 52W Low
- ₹97.59
- Day Range
- ₹104.98 – ₹110.89
- Volume
- 29,279
Peer Comparison
Healthcare › Healthcare Services › Hospitals › Hospital
| ₹8,599.50 | 59.18 | ₹1,22,850 Cr | 13.04 | 0.24% | 21.20% | 17.40% | ₹26,430 Cr | ₹2,171 Cr | |
| ₹927.15 | 61.89 | ₹89,301 Cr | 7.96 | 0.22% | 14.70% | 14.70% | ₹8,712 Cr | ₹1,457 Cr | |
| ₹667.20 | 88.96 | ₹86,479 Cr | 5.34 | 0.00% | 6.64% | 8.30% | ₹11,400 Cr | ₹906 Cr | |
| ₹719.55 | 117.00 | ₹59,927 Cr | 14.91 | 0.44% | 11.30% | 11.60% | ₹4,876 Cr | ₹363 Cr | |
| ₹790.65 | 56.96 | ₹59,706 Cr | 6.03 | 0.13% | 11.20% | 13.40% | ₹9,506 Cr | ₹1,070 Cr | |
| ₹1,931.50 | 48.36 | ₹39,090 Cr | 7.89 | 0.24% | 20.50% | 15.50% | ₹9,072 Cr | ₹816 Cr | |
| ₹1,402.00 | 67.76 | ₹37,618 Cr | 9.52 | 0.04% | 15.20% | 17.40% | ₹4,683 Cr | ₹552 Cr | |
| Lotus Eye Hospital (this company) | ₹106.52 | 1,521.71 | ₹225 Cr | 3.68 | 0.46% | 0.13% | 1.41% | ₹57 Cr | ₹0 Cr |
| Median 8 companies | ₹858.90 | 64.83 | ₹59,817 Cr | 7.93 | 0.23% | 13.00% | 14.05% | ₹8,892 Cr | ₹861 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
37 Weak
Data confidence 100/100
pledge:87%
Category scores
- Quality
- 46
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 21
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 57
- Good
- Sales & profit trajectory 9% weight
- Financial Health
- 50
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 41
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
Capped: a governance trigger overrides the
fundamentals here (pledge>75% ≤ 40).
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
7- Stock is trading at 3.70 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 10.7% over past five years.
- Company has a low return on equity of 2.09% over last 3 years.
- Promoters have pledged 87.2% of their holding.
- Promoter holding has decreased over last 3 years: -17.4%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 4 | 3 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bullish
Bearish
2
Neutral
4
Bullish
3
Overall
Strong Bearish
Bearish
12
Neutral
4
Bullish
3
Moving Averages
Strong Bearish
Bearish
10
Neutral
0
Bullish
0
Key readings
- RSI (14)
- 38.18
- Neutral
- MACD (12,26,9)
- −1.34
- Bearish
- SMA (50)
- 111.96
- Bearish
- SMA (200)
- 115.24
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +5.60% |
|---|---|
| 5Y | +10.67% |
| 3Y | +4.52% |
| 1Y | +8.38% |
| TTM | +14.09% |
Net profit
| 10Y | −2.21% |
|---|---|
| 5Y | −44.86% |
| 3Y | −73.03% |
| 1Y | −89.19% |
| TTM | −76.92% |
Operating cash flow
| 10Y | −1.12% |
|---|---|
| 5Y | +2.04% |
| 3Y | −11.72% |
| 1Y | +11.85% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −6.21 pp |
|---|---|
| 5Y | −4.58 pp |
| 3Y | −9.72 pp |
| 1Y | −0.57 pp |
| TTM | +2.01 pp |
Revenue by year
| Mar 2017 | ₹33.96 Cr |
|---|---|
| Mar 2018 | ₹38.02 Cr |
| Mar 2019 | ₹38.43 Cr |
| Mar 2020 | ₹40.55 Cr |
| Mar 2021 | ₹32.35 Cr |
| Mar 2022 | ₹38.90 Cr |
| Mar 2023 | ₹47.03 Cr |
| Mar 2024 | ₹48.20 Cr |
| Mar 2025 | ₹49.55 Cr |
| Mar 2026 | ₹53.70 Cr |
Net profit by year
| Mar 2017 | ₹0.44 Cr |
|---|---|
| Mar 2018 | ₹1.75 Cr |
| Mar 2019 | ₹0.71 Cr |
| Mar 2020 | ₹1.06 Cr |
| Mar 2021 | ₹1.57 Cr |
| Mar 2022 | ₹2.98 Cr |
| Mar 2023 | ₹4.08 Cr |
| Mar 2024 | ₹2.91 Cr |
| Mar 2025 | ₹0.74 Cr |
| Mar 2026 | ₹0.08 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.57 | 12.73 | 12.03 | 10.88 | 12.89 | 12.91 | 12.25 | 11.51 | 13.52 | 13.04 | 13.55 | 13.61 | 17.06 |
| Expenses | 10.18 | 10.92 | 10.45 | 10.12 | 11.23 | 11.76 | 11.46 | 11.68 | 12.04 | 12.27 | 12.89 | 13.13 | 14.11 |
| Operating Profit | 2.39 | 1.81 | 1.58 | 0.76 | 1.66 | 1.15 | 0.79 | −0.17 | 1.48 | 0.77 | 0.66 | 0.48 | 2.95 |
| OPM % | 19.01% | 14.22% | 13.13% | 6.99% | 12.88% | 8.91% | 6.45% | −1.48% | 10.95% | 5.9% | 4.87% | 3.53% | 17.29% |
| Other Income | 0.29 | 0.27 | 0.35 | 0.4 | 0.31 | 0.26 | 0.22 | 0.52 | 0.19 | 0.27 | 0.24 | 0.47 | 0.21 |
| Interest | 0.02 | 0.01 | 0.04 | 0.03 | 0.06 | 0.08 | 0.13 | 0.09 | 0.12 | 0.12 | 0.29 | 0.33 | 0.51 |
| Depreciation | 0.73 | 0.89 | 0.98 | 1.12 | 1.06 | 1.23 | 1.31 | −0.58 | 0.82 | 0.85 | 0.98 | 1.1 | 1.64 |
| PBT | 1.93 | 1.19 | 0.9 | 0.01 | 0.86 | 0.11 | −0.43 | 0.84 | 0.73 | 0.07 | −0.37 | −0.48 | 1.01 |
| Tax % | 27.98% | 28.57% | 26.67% | −200% | 28.24% | 9.09% | −44.19% | 70.24% | 24.66% | −71.43% | −29.73% | −33.33% | 39.6% |
| Net Profit | 1.38 | 0.85 | 0.66 | 0.02 | 0.62 | 0.1 | −0.24 | 0.25 | 0.54 | 0.12 | −0.26 | −0.32 | 0.61 |
| EPS (₹) | 0.66 | 0.41 | 0.32 | 0.01 | 0.3 | 0.05 | −0.12 | 0.12 | 0.26 | 0.06 | −0.13 | −0.15 | 0.29 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29.9 | 31.13 | 33.96 | 38.02 | 38.43 | 40.55 | 32.35 | 38.9 | 47.03 | 48.2 | 49.55 | 53.7 | 57.26 |
| Expenses | 27.72 | 27.14 | 30.63 | 33.68 | 35.21 | 36.57 | 28.73 | 32.98 | 39.35 | 41.57 | 45.99 | 50.15 | 52.4 |
| Operating Profit | 2.18 | 3.99 | 3.33 | 4.34 | 3.22 | 3.98 | 3.62 | 5.92 | 7.68 | 6.63 | 3.56 | 3.55 | 4.86 |
| OPM % | 7.29% | 12.82% | 9.81% | 11.42% | 8.38% | 9.82% | 11.19% | 15.22% | 16.33% | 13.76% | 7.18% | 6.61% | 8.49% |
| Other Income | 0.46 | 0.58 | 0.68 | 0.91 | 0.68 | 0.21 | 0.84 | 0.88 | 1.15 | 1.31 | 1.31 | 1.18 | 1.19 |
| Interest | 0.1 | 0.16 | 0.15 | 0.18 | 0.21 | 0.24 | 0.14 | 0.21 | 0.2 | 0.2 | 0.48 | 1.03 | 1.25 |
| Depreciation | 4.76 | 4.44 | 3.44 | 3.37 | 3.06 | 2.5 | 2.33 | 2.5 | 2.98 | 3.73 | 3.01 | 3.75 | 4.57 |
| PBT | −2.22 | −0.03 | 0.42 | 1.7 | 0.63 | 1.45 | 1.99 | 4.09 | 5.65 | 4.01 | 1.38 | −0.05 | 0.23 |
| Tax % | −10.81% | −400% | −7.14% | −2.35% | −12.7% | 26.9% | 21.11% | 27.14% | 27.79% | 27.43% | 46.38% | −280% | — |
| Net Profit | −1.98 | 0.1 | 0.44 | 1.75 | 0.71 | 1.06 | 1.57 | 2.98 | 4.08 | 2.91 | 0.74 | 0.08 | 0.15 |
| EPS (₹) | −0.95 | 0.05 | 0.21 | 0.84 | 0.34 | 0.51 | 0.75 | 1.43 | 1.96 | 1.4 | 0.36 | 0.04 | 0.07 |
| Div. Payout % | 0% | 0% | 236.36% | 59.43% | 0% | 0% | 66.24% | 34.9% | 25.49% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20.8 | 20.8 | 20.8 | 20.8 | 20.8 | 20.8 | 20.8 | 20.8 | 20.8 | 20.8 | 20.8 | 20.8 |
| Reserves | 28.59 | 28.69 | 29.26 | 29.84 | 29.32 | 30.46 | 31.9 | 33.81 | 36.78 | 38.61 | 39.2 | 39.34 |
| Borrowings | 0.83 | 0.66 | 0.48 | 0.29 | 0.22 | 0.32 | 0.4 | 1.24 | 0.67 | 1.11 | 3.43 | 15.83 |
| Other Liabilities | 6.2 | 4.68 | 4.4 | 7.28 | 6.18 | 6.53 | 6.12 | 5.75 | 4.93 | 6.11 | 6.14 | 6.63 |
| Total Liabilities | 56.42 | 54.83 | 54.94 | 58.21 | 56.52 | 58.11 | 59.22 | 61.6 | 63.18 | 66.63 | 69.57 | 82.6 |
| Fixed Assets | 47.04 | 43.57 | 41.32 | 42.52 | 44.14 | 42.67 | 40.54 | 44.07 | 44.18 | 48.65 | 54.07 | 65.81 |
| CWIP | 0.27 | 0.42 | 0.65 | 0.29 | 0.29 | 0 | 0 | 0 | 0 | 0.08 | 0 | 0.09 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 9.11 | 10.84 | 12.97 | 15.4 | 12.09 | 15.44 | 18.68 | 17.53 | 19 | 17.9 | 15.5 | 16.7 |
| Total Assets | 56.42 | 54.83 | 54.94 | 58.21 | 56.52 | 58.11 | 59.22 | 61.6 | 63.18 | 66.63 | 69.57 | 82.6 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 2.37 | 3.38 | 2.97 | 5.78 | 4.2 | 4.97 | 2.73 | 4.41 | 4.39 | 5.68 | 2.7 | 3.02 |
| Investing | −4.65 | −0.85 | −1.06 | −3.86 | −4.01 | −0.68 | 0.49 | −3.94 | −2.19 | −4.63 | −6.13 | −14.39 |
| Financing | 1.87 | −0.58 | −0.25 | −1.51 | −1.41 | 0.13 | −0.32 | −1.58 | −1.71 | −3.4 | −1.6 | 9.03 |
| Net Cash Flow | −0.4 | 1.96 | 1.66 | 0.41 | −1.22 | 4.42 | 2.9 | −1.1 | 0.49 | −2.35 | −5.03 | −2.34 |
| Free Cash Flow | −2.38 | 2.28 | 1.55 | 1.58 | −0.49 | 3.54 | 2.61 | −0.25 | 1.3 | 0.1 | −2.09 | −10.01 |
| CFO/OP | 109 | 85 | 92 | 142 | 134 | 132 | 84 | 89 | 76 | 101 | 94 | 94 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 4.27 | 5.98 | 7.31 | 10.94 | 7.22 | 5.94 | 8.35 | 5.82 | 9.08 | 9.54 | 9.72 | 8.22 |
| Inventory Days | 122 | 113 | 60.22 | 79.23 | 128 | 124 | 139 | 150 | 154 | 170 | 194 | 172 |
| Days Payable | 125 | 106 | 87.32 | 130 | 167 | 170 | 221 | 231 | 173 | 184 | 170 | 146 |
| Cash Conversion Cycle | 0.73 | 13.72 | −19.79 | −39.78 | −31.95 | −40.05 | −73.54 | −75.37 | −10.74 | −3.72 | 33.48 | 34.3 |
| Working Capital Days | −19.9 | −8.56 | −8.92 | −26.02 | −15.39 | −21.33 | −23.92 | −16.33 | 8.61 | 5.68 | 0 | −12.17 |
| ROCE % | −4.23% | 0.24% | 1.19% | 3.63% | 1.66% | 4.67% | 3.92% | 7.91% | 10.25% | 7.07% | 2.99% | 1.41% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Lotus Eye Hospital insights
61 extracted metrics across FY11–FY27.
Documents
- 11 Feb 2026
- General announcements 8 Oct 2026
Frequently Asked Questions about Lotus Eye Hospital & Institute
What does Lotus Eye Hospital & Institute Ltd do?
Incorporated in 1990, Lotus Eye Hospital and Institute Ltd provides ophthalmology and other related services.
Where is Lotus Eye Hospital & Institute Ltd (LOTUSEYE) listed?
Lotus Eye Hospital & Institute Ltd trades as LOTUSEYE on the NSE and under code 532998 on the BSE.
Which sector does Lotus Eye Hospital & Institute Ltd belong to?
Lotus Eye Hospital & Institute Ltd is classified under the Healthcare Services sector, in the Hospitals industry.
What is the PE ratio of Lotus Eye Hospital & Institute Ltd?
Lotus Eye Hospital & Institute Ltd trades at a PE ratio of 1521.71 as of 4 Nov 2026, on earnings per share of ₹0.07, against a book value of ₹28.92 per share.
What is the 52-week high and low of Lotus Eye Hospital & Institute Ltd?
Over the last 52 weeks Lotus Eye Hospital & Institute Ltd has traded between ₹97.59 and ₹147 as of 4 Nov 2026.
Does Lotus Eye Hospital & Institute Ltd pay dividends?
Lotus Eye Hospital & Institute Ltd has a dividend yield of 0.46%.
What is the Return on Equity (ROE) of Lotus Eye Hospital & Institute Ltd?
Lotus Eye Hospital & Institute Ltd reported a return on equity of 0.13%. Its debt-to-equity ratio is 0.26.
Company Information
Incorporated in 1990, Lotus Eye Hospital and Institute Ltd provides ophthalmology and other related services.
Website lotuseye.org
CEO Ms. Sangeetha Sundaramoorthy
Employees 348
Listed 11 Jul 2008
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LOTUSEYE.md for Lotus Eye Hospital & Institute Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.